Rituxan rituximab anti-CD20 monoclonal antibody regulatory update

IDPH said the FDA completed a review of its sBLA for Rituxan to include in the product's label treatment of bulky non-Hodgkin's lymphoma (NHL), up to eight weekly doses per treatment, and multiple cou...